» Articles » PMID: 11829344

Histopathological-molecular Genetic Correlations in Referral Pathologist-diagnosed Low-grade "oligodendroglioma"

Overview
Specialties Neurology
Pathology
Date 2002 Feb 7
PMID 11829344
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Allelic loss of chromosome 1p predicts increased chemosensitivity and better survival in oligodendroglial tumors. Clinical testing for 1p loss in oligodendroglial tumors at our hospital has allowed us to postulate that certain histological appearances are associated with 1p allelic status. Forty-four cases received for genetic testing were diagnosed by referring pathologists as pure low-grade oligodendroglioma. Central neuropathological review divided the series equally into 22 cases with classical oligodendroglioma histology and 22 with more astrocytic features. Molecular genetic analyses demonstrated 1p loss in 19 of 22 classic oligodendrogliomas (86%) and maintenance of both 1p alleles in 16 of 22 gliomas with astrocytic features (73%). No glial fibrillary acidic protein-positive cell type (gliofibrillary oligodendrocyte, minigemistocyte, cellular processes) was associated with 1p allelic status. Fourteen of the 44 cases were treated with chemotherapy at tumor progression: 3 "astrocytic" gliomas with 1p loss responded to PCV chemotherapy and 2 classic oligodendrogliomas that maintained both 1p alleles included a responder and a non-responder. These results suggest that histological appearance correctly predicts genotype in approximately 80% of low-grade gliomas, but that tumor genotype more closely predicts chemosensitivity. As a result, such objective molecular genetic analyses should be incorporated into patient management and into clinical trials of low-grade diffuse gliomas.

Citing Articles

Biological functions of the Olig gene family in brain cancer and therapeutic targeting.

Szu J, Tsigelny I, Wojcinski A, Kesari S Front Neurosci. 2023; 17:1129434.

PMID: 37274223 PMC: 10232966. DOI: 10.3389/fnins.2023.1129434.


Comparative evaluation of intracranial oligodendroglioma and astrocytoma of similar grades using conventional and T1-weighted DCE-MRI.

Gupta M, Gupta A, Yadav V, Parvaze S, Singh A, Saini J Neuroradiology. 2021; 63(8):1227-1239.

PMID: 33469693 DOI: 10.1007/s00234-021-02636-8.


Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma.

Gimenez M, Marie S, Oba-Shinjo S, Uno M, Izumi C, Oliveira J BMC Cancer. 2015; 15:481.

PMID: 26108672 PMC: 4502388. DOI: 10.1186/s12885-015-1473-9.


Molecular-genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort.

Hayashi S, Sasaki H, Kimura T, Abe T, Nakamura T, Kitamura Y Oncotarget. 2015; 6(18):15871-81.

PMID: 25991674 PMC: 4599243. DOI: 10.18632/oncotarget.3869.


Pathology and genetics of diffuse gliomas in adults.

Komori T Neurol Med Chir (Tokyo). 2015; 55(1):28-37.

PMID: 25744348 PMC: 4533400. DOI: 10.2176/nmc.ra.2014-0229.